RNS Number : 3061G Renalytix PLC 23 July 2021 Renalytix plc (" Renalytix " or the " Company ") Director/PDMR Dealing New York , 23 July 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling , the Company's Chief Financial Officer, of 12,000
RNS Number : 0685G Renalytix PLC 22 July 2021 Renalytix plc (" Renalytix " or the " Company ") Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory Hutson To Build-on Renalytix Quality and Regulatory Strategy for KidneyIntelX Global Commercialization NEW YORK
RNS Number : 7167F Renalytix PLC 19 July 2021 Renalytix plc (" Renalytix " or the " Company ") Exercise of Options and TVR NEW YORK , 19 July, 2021 - Renalytix plc (AIM: RENX) announces that it has issued and allotted 5,000 ordinary shares of 0.25 pence each in the share capital of the
RNS Number : 3722E Renalytix PLC 07 July 2021 Renalytix plc (" Renalytix " or the " Company ") Exercise of options, PDMR transaction and TVR NEW YORK , 7 July, 2021 - The Board of Renalytix plc (LSE: RENX) announces that it has issued and allotted 27,500 ordinary shares of 0.25 pence
RNS Number : 9118D Renalytix PLC 01 July 2021 Renalytix plc (" Renalytix " or the " Company ") Death of Director NEW YORK , 1 July, 2021 - The Board of Renalytix plc (LSE: RENX) (NASDAQ: RNLX) is saddened to announce the death of Dr. Barbara Murphy , Non-Executive Director and
RNS Number : 7147D Renalytix PLC 01 July 2021 Renalytix plc (" Renalytix " or the " Company ") Total voting rights The Company's total issued share capital consists of 72,197,286 shares of 0.25 pence each, with each share carrying the right to one vote.
RNS Number : 3397D Renalytix PLC 28 June 2021 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company had been informed today that Christopher Mills , a non-executive director and interim Chairman, completed the sale of 6,100 ordinary shares of 0.25 pence each
RNS Number : 2844D Renalytix PLC 28 June 2021 Renalytix plc (" Renalytix " or the " Company ") KidneyIntelX TM Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and
RNS Number : 2249D Renalytix PLC 25 June 2021 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Fergus Fleming , Chief Technology Officer, completed the sale of 15,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the
RNS Number : 1945D Renalytix PLC 25 June 2021 Renalytix plc (" Renalytix " or the " Company ") Exercise of options and total voting rights NEW YORK , June 25, 2021 - Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces that it has issued and allotted 150,000 ordinary shares of 0.25 pence
